Analyst Price Target is $4.71
▲ +249.21% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for 9 Meters Biopharma in the last 3 months. The average price target is $4.71, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 249.21% upside from the last price of $1.35.
Current Consensus is
The current consensus among 9 polled investment analysts is to buy stock in 9 Meters Biopharma. This rating has held steady since October 2019, when it changed from a Hold consensus rating.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.